Fruitful partnerships
VelosBio marks the first start-up to emerge from Arix’s partnerships
Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit.
Also participating in the round, which closed Oct. 1., were co-lead investor Sofinnova Ventures, new investors Pappas Ventures and Chiesi Ventures and fellow existing investor Decheng Capital.
Arix launched in 2016 and raised £100 million ($130.5 million) in an IPO on...
Read the full 351 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury
Article Purchase
$150 USD
